Goldman Sachs
KZR

Goldman Sachs’s Kezar Life Sciences KZR Stock Holding History

Goldman Sachs’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,178
Closed -$138K – 6274
2025
Q1 		$138K Sell
28,178
-24,094
-46% -$146K ﹤0.01% 5724
2024
Q4 		$351K Buy
52,272
+22,495
+76% +$168K ﹤0.01% 5424
2024
Q3 		$230K Sell
29,777
-72,141
-71% -$435K ﹤0.01% 5407
2024
Q2 		$612K Buy
101,918
+61,447
+152% +$467K ﹤0.01% 4718
2024
Q1 		$365K Sell
40,471
-3,801
-9% -$34.6K ﹤0.01% 4885
2023
Q4 		$419K Sell
44,272
-94,229
-68% -$828K ﹤0.01% 4856
2023
Q3 		$1.65M Buy
138,501
+4,004
+3% +$71K ﹤0.01% 3917
2023
Q2 		$3.3M Buy
134,497
+26,287
+24% +$684K ﹤0.01% 3471
2023
Q1 		$3.39M Buy
108,210
+62,884
+139% +$3.64M ﹤0.01% 3416
2022
Q4 		$3.19M Sell
45,326
-50,033
-52% -$3.71M ﹤0.01% 3560
2022
Q3 		$8.21M Buy
95,359
+27,102
+40% +$2.63M ﹤0.01% 2685
2022
Q2 		$5.64M Buy
68,257
+42,337
+163% +$3.73M ﹤0.01% 3023
2022
Q1 		$4.31M Buy
25,920
+17,300
+201% +$2.48M ﹤0.01% 3488
2021
Q4 		$1.44M Sell
8,620
-18,754
-69% -$2.12M ﹤0.01% 4531
2021
Q3 		$2.37M Buy
27,374
+15,718
+135% +$1.04M ﹤0.01% 4034
2021
Q2 		$633K Buy
11,656
+1,521
+15% +$86.4K ﹤0.01% 5082
2021
Q1 		$604K Buy
10,135
+1,270
+14% +$74.2K ﹤0.01% 4978
2020
Q4 		$462K Buy
8,865
+1,416
+19% +$78.8K ﹤0.01% 4652
2020
Q3 		$360K Buy
7,449
+2,047
+38% +$97.9K ﹤0.01% 4642
2020
Q2 		$280K Buy
5,402
+3,416
+172% +$172K ﹤0.01% 4660
2020
Q1 		$87K Buy
1,986
+149
+8% +$6.06K ﹤0.01% 4964
2019
Q4 		$74K Sell
1,837
-2,530
-58% -$77.9K ﹤0.01% 5085
2019
Q3 		$143K Buy
4,367
+2,910
+200% +$141K ﹤0.01% 4910
2019
Q2 		$112K Buy
+1,457
New +$227K ﹤0.01% 4908
2018
Q3 		– Sell
-2,500
Closed -$433K – 5701
2018
Q2 		$433K Buy
+2,500
New +$436K ﹤0.01% 4598

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Goldman Sachs's KZR Position: Q2 2025 in Review

Goldman Sachs sold out of Kezar Life Sciences (KZR) in Q2 2025, closing a stake of 28,178 shares — an estimated $138K sold.

Goldman Sachs first reported a position in KZR in Q2 2018 and held it in 25 quarters. The position peaked at $8.21M in Q3 2022. 40 funds tracked by Wall St. Rank hold KZR as of Q2 2025.

  • Goldman Sachs reported no remaining Kezar Life Sciences position as of Q2 2025 after selling out during the quarter.
  • Goldman Sachs sold 28,178 Kezar Life Sciences shares in Q2 2025, an estimated $138K.
  • Goldman Sachs first reported a position in Kezar Life Sciences in Q2 2018 and held it in 25 quarters.
  • Goldman Sachs's Kezar Life Sciences position peaked at $8.21M in Q3 2022.
  • 40 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2025.

Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.